Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when IONS files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsIonis reports positive pivotal trial for zilganersen in Alexander disease; FDA decision Sept 22
Filed April 21, 2026 · Period ending April 21, 2026 · ~1 min read
Key Changes
-
high
Zilganersen met primary endpoint, stabilizing gait speed in patients ≥5 years (33.3% improvement, p=0.041) and improving gross motor function in children 2-4 years (22.9 points, nominal p=0.034) in pivotal Alexander disease study.
Item 8.01 — Other Events verify on EDGAR → -
high
FDA Priority Review underway with PDUFA action date September 22, 2026 for zilganersen, which would be first disease-modifying treatment for Alexander disease, a rare and often fatal neurological condition.
Item 8.01 — Other Events verify on EDGAR → -
high
Patient-reported outcomes strongly favored zilganersen: 32% rated most bothersome symptom "much better" vs 0% on control; only 5% rated "much worse" vs 31% on control.
Item 8.01 — Other Events verify on EDGAR → -
medium
Safety profile favorable with most adverse events mild/moderate; serious adverse events occurred less frequently with zilganersen (37.5%) than control (47.1%).
Item 8.01 — Other Events verify on EDGAR → -
medium
Exploratory biomarker analysis showed zilganersen reduced plasma GFAP levels by 33.6% vs control (nominal p=0.003), validating mechanism targeting toxic protein accumulation.
Exhibit 99.1 view on EDGAR →
Summary
Ionis announced positive results from the pivotal study of zilganersen in Alexander disease, a rare and often fatal neurological disorder with no approved treatments. The study met its primary endpoint, demonstrating statistically significant stabilization of gait speed in patients 5 years and older, with additional data showing improvement in gross motor function in younger children aged 2-4 years.
Patient-reported outcomes consistently favored zilganersen across multiple measures, with 32% of patients reporting their most bothersome symptom as "much better" compared to none on control. The FDA has granted Priority Review with a PDUFA action date of September 22, 2026, making this a near-term regulatory catalyst.
If approved, zilganersen would become the first disease-modifying treatment for Alexander disease, which affects approximately 1 per 1-3 million people worldwide. The favorable safety profile, with serious adverse events occurring less frequently than in the control group, supports the drug's regulatory and commercial prospects. The September decision date represents a significant milestone for Ionis shareholders, as approval would validate the company's antisense oligonucleotide platform in another rare disease indication.
Section-by-Section Diff
Event · Item 7.01 — Regulation FD Disclosure
Item 7.01 — Regulation FD Disclosure filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On April 21, 2026, Ionis Pharmaceuticals, Inc. (“Ionis,” “we,” “us” or “our company”) issued a press release announcing additional positive results from the pivotal study of zilganersen in children and adults living with Alexander disease (“AxD”).
Ionis disclosed additional positive results from the pivotal study of zilganersen, a drug candidate for Alexander disease, in both children and adults. The 8-K references a press release but does not provide specific efficacy or safety data within the filing itself. Pivotal study results are critical for regulatory approval pathways and can significantly impact the drug's commercial prospects.
Event · Item 8.01 — Other Events
Ionis announced positive pivotal study results for zilganersen in Alexander disease, meeting primary endpoint with FDA action date Sept 22, 2026.
Added in current filing · verify on EDGAR →
Zilganersen is currently under Priority Review by the U.S. Food and Drug Administration with a Prescription Drug User Fee Act action date of September 22, 2026.
The FDA has granted Priority Review for zilganersen with a PDUFA action date of September 22, 2026. This accelerated review timeline reflects the FDA's recognition of the drug's potential to address an unmet medical need in a rare disease with no approved treatments. The upcoming decision date is a key near-term catalyst for investors.
Event · Exhibit 99.1
Added in current filing · verify on EDGAR →
The study met its primary endpoint in individuals ≥5 years of age, with zilganersen 50 mg demonstrating statistically significant and clinically meaningful stabilization of gait speed as assessed by the 10-Meter Walk Test (10MWT), compared to control at Week 61 ... New data from the Gross Motor Function Measure-88 (GMFM-88), a well-established motor endpoint, supports the primary outcome of the study by demonstrating that treatment with zilganersen may improve gross motor function in younger children (2-4 years of age), compared to control.
Ionis disclosed that zilganersen met its primary endpoint in a pivotal study for Alexander disease, showing statistically significant stabilization of gait speed in patients 5 years and older. Additional data showed potential improvement in gross motor function in younger children aged 2-4 years. These results support zilganersen's potential as the first disease-modifying treatment for this rare, progressive, and often fatal neurological condition.
Added in current filing · verify on EDGAR →
Zilganersen is currently under Priority Review by the U.S. Food and Drug Administration (FDA) with a Prescription Drug User Fee Act (PDUFA) action date of September 22, 2026.
The FDA has set a PDUFA action date of September 22, 2026 for zilganersen, which is under Priority Review. This regulatory milestone represents a potential near-term catalyst for Ionis, as approval would bring the first disease-modifying treatment to market for Alexander disease, a condition affecting approximately 1 per 1 to 3 million people worldwide.
Added in current filing · verify on EDGAR →
In an exploratory analysis, zilganersen reduced plasma GFAP levels by 33.6% at Week 61 compared to control (nominal1 p=0.003)2, consistent with its mechanism of targeting GFAP RNA in the central nervous system.
Exploratory biomarker data showed zilganersen reduced plasma GFAP levels by 33.6% compared to control, validating the drug's mechanism of action in targeting the underlying cause of Alexander disease. This reduction in the toxic protein that accumulates in the disease provides biological evidence supporting the clinical benefits observed in the study.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 21, 2026 · How we verify